Skip to content

Study on Complications, EfficAcy and Costs of Large Polypectomy

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT02694120
Acronym
SCALP
Enrollment
1000
Registered
2016-02-29
Start date
2016-02-29
Completion date
Unknown
Last updated
2016-02-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Polypectomy

Brief summary

Colonoscopy has been shown to reduce the incidence and mortality of colorectal cancer, through the recognition and removal of pre-cancerous lesions, which in most cases evolve with a sequence that goes through formation of high-grade dysplasia (HGD). The probability of HGD increases with the increase of the lesion of the polyp itself. Lesions\> 2 cm are present in 1% of colonoscopy screening. The resection of these lesions presents a greater technical difficulty and consequently a decrease in the efficiency. The rate of incomplete resection reported in the literature reaches 10% while that of recurrence / residual adenoma 16.4 / 31.7%. The aim of the study SCALP is to evaluate the incidence of complications, efficacy and cost of endoscopic resection of colic lesions\> 2cm in a setting of clinical practice in an unselected population

Interventions

None listed

Sponsors

Valduce Hospital
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* adult patients undergoing large endoscopic polypectomy

Exclusion criteria

* pregnancy * incapacity to give informed consent

Design outcomes

Primary

MeasureTime frameDescription
complications of large polypectomy15 daysincidence of polypectomy-related adverse events

Secondary

MeasureTime frameDescription
costs of large polypectomy15 daysassessment of the average cost per procedure, including devices and staff costs
efficacy of large polypectomy6 monthsassessment of residual adenoma at follow-up

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 20, 2026